Brief: Xvivo Perfusion: Breakthrough Device Designation For Heart Preservation System
Dec 16 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* XVIVO PERFUSION GRANTED BREAKTHROUGH DEVICE DESIGNATION FROM THE FDA FOR THE XVIVO HEART
PRESERVATION SYSTEM
Source text for Eikon: ID:nWkrjQvdR
Further company coverage: XVIVO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength